Butylated hydroxytoluene displays significant antioxidant activity across a multitude of assays and concentrations. It demonstrates a notable ability to inhibit lipid peroxidation in various tissues, including rat brain and liver microsomes, with IC50 values ranging from 0.1 µg/mL to 59,000 nM. Its time-dependent antioxidative properties are evident in AAPH-induced MDA assays and other experimental setups, showing decreased activity over longer incubations.
Additionally, Butylated hydroxytoluene exhibits a range of radical scavenging activities, including DPPH, ABTS, nitric oxide, hydroxyl, and superoxide radicals. It shows variable efficacy in different assays, with IC50 values for DPPH radical scavenging reported between 16.47 µg/mL and 90900 nM. It also inhibits lipid peroxidation induced by ferrous ions and AAPH in different models.
Moreover, Butylated hydroxytoluene has shown neuroprotective and cytoprotective effects, demonstrated by its ability to protect cerebellar granule cells from iodoacetate-induced toxicity and to inhibit cellular death in C6 glial cells. It has been reported to enhance recovery from coma, evidenced by improved survival times and behavioral responses in mice.
The compound also exhibits anti-hypoxic, anti-inflammatory, and enzyme regulatory activities. It inhibits human erythrocyte CA1 and CA2 esterase activity, as well as platelet aggregation induced by platelet-activating factors. Furthermore, Butylated hydroxytoluene has a potential use in reducing oxidative stress and protecting against cellular damage in ischemic conditions.
Finally, the compound shows antibacterial and antibiofilm activities, against strains like Vibrio harveyi, and demonstrates synergistic effects when combined with other agents. Its ability to inhibit quorum sensing, reduce biofilm formation, and enhance cell viability in infected organisms highlights its potential therapeutic applications in infectious diseases..
Note: Summary generated by AI. Data source: ChEMBL 